Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Bioorthogonal Cascade-Targeting: Directing Drugs into Cells with Molecular Precision

Project description

Navigating drugs into cancer cells

The specificity of drug delivery is paramount to avoiding toxicity and other drug-related side effects. However, shuttling therapeutic agents to specific cells or within cells remains a significant challenge. Funded by the European Research Council, the bioTARGET project proposes to develop a chemically controlled approach that will achieve specific intracellular delivery of therapeutics with molecular precision. The strategy relies on bioorthogonal chemistry that does not interfere with native biochemical processes. Researchers will design activatable ligands with spatial and temporal control features for the delivery and release of therapeutics within cells.

Objective

Bioorthogonal chemistries cross the boundaries between static chemical connectivity and the dynamic physiologic regulation of molecular state, enabling powerful tools for molecular control in complex biological environments. In combination with ligand-directed drug delivery, safe and selective chemical reactions that perform efficiently in vivo can fuel the design of new therapeutic strategies. Despite significant progress in the field of drug targeting, it remains challenging to shuttle therapeutic agents to the desired tissue, reaching the necessary cellular and even sub-cellular level, all while avoiding collateral damage. To engage this challenge, I aim to develop the concept of bioorthogonal cascade-targeting to direct the recognition, activation, and intracellular delivery of therapeutic constructs with molecular precision. We will develop next-level chemical tools for bioorthogonal bond-cleavage with exceptional reaction performance and the unique capability of tunable sequential release events (‘tandem release’). These innovations will enable us to design bioorthogonally activatable ligands for multiple therapeutic approaches that open new ground, most notably in escalating the complexity of (bio)chemical choreography. In particular, I propose cascade-processes, triggered by a single biocompatible click event, that can achieve: (i) the ‘bridging’ of non-internalizing cell-surface receptors to forward therapeutics into cells; (ii) the ‘hopping’ of drug conjugates from one target to another, or from one cell to another; and (iii) kinetically preprogrammed ‘escape’ of drugs from the endosomal compartment of cells entered via cascade-targeting. This will allow us to spatially and temporally control the movement and release of therapeutics in a (sub)cellular environment, and ultimately to establish bioorthogonal cascades as unique strategies that shift the paradigm of biologically controlled drug delivery.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2021-STG

See all projects funded under this call

Host institution

TECHNISCHE UNIVERSITAET WIEN
Net EU contribution
€ 1 479 321,00
Address
KARLSPLATZ 13
1040 Wien
Austria
Region
Ostösterreich Wien Wien
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 479 321,00

Beneficiaries (1)